Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis

Ivan Stankovic, Ivan Stanković, Alja Vlahovic-Stipac, Alja Vlahović-Stipac, Biljana Putnikovic, Biljana Putniković, Zorica Cvetković, Zorica Cvetkovic, Aleksandar Nešković, Aleksandar N Neskovic
Clinical therapeutics · 2010 · vol. 32(5) , pp. 909–914 · doi:10.1016/j.clinthera.2010.04.017 · PMID:20685498 · W2005762277
article OA: closed CC0 ⤵ 1 in-corpus citation
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

This case report describes a fatal instance of rhabdomyolysis in a patient who was concomitantly administered simvastatin and danazol.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Danazol Estrogen Antagonists Hydroxymethylglutaryl-CoA Reductase Inhibitors Rhabdomyolysis Simvastatin Aged Aged, 80 and over Danazol Drug Interactions Estrogen Antagonists Fatal Outcome Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Male Rhabdomyolysis Simvastatin

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-16T06:07:01.518242+00:00
openalex
last seen: 2026-05-11T06:40:38.933960+00:00
pubmed
last seen: 2026-05-13T22:17:07.008521+00:00
License: CC0 · commercial use OK